Stay updated on Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe record history now shows the current page revision as v3.6.5, replacing the previous v3.6.4. This is a metadata update indicating the page was refreshed to the latest version.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedA new revision entry (v3.6.4) was added to the history, representing an update to the study record. The previous revision (v3.6.3) was removed from the change log.SummaryDifference0.1%

- Check51 days agoChange DetectedA new revision entry (v3.6.3) was added to the history, and the previous revision (v3.6.2) was removed from the current listing, updating the page's version history.SummaryDifference0.1%

- Check58 days agoChange DetectedA new revision entry v3.6.2 was added to the history, and the previous entry v3.6.0 was removed, updating the study's submission record.SummaryDifference0.1%

- Check72 days agoChange DetectedThe history now shows recruitment status updated to no longer looking for participants and a new Revision: v3.6.0 added, replacing the previous Revision: v3.5.5.SummaryDifference0.3%

- Check79 days agoChange DetectedA new revision entry v3.5.5 appears in the study record history, and the previous revision v3.5.4 is no longer listed. This change updates the history log metadata for the record.SummaryDifference0.1%

Stay in the know with updates to Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page.